A5029819175- CAR-T cell therapy research
- Virus-based gene therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Immune Cell Function and Interaction
- Polyomavirus and related diseases
Institute of Haematology and Blood Transfusion
2018-2024
Charles University
2020-2024
The piggyBac transposon system provides a non-viral alternative for cost-efficient and simple chimeric antigen receptor (CAR) T cell production. generation of clinical-grade CAR cells requires strict adherence to current good manufacturing practice (cGMP) standards. Unfortunately, the high costs commonly used lentiviral or retroviral vectors limit in many non-commercial academic institutions. Here, we present platform highly efficient CD19-specific (CAR19 cells) based on co-electroporation...
Tisagenlecleucel (tisa-cel) is a CD19 - specific CAR-T cell product approved for the treatment of relapsed/refractory (r/r) DLBCL or B-ALL. We have followed group patients diagnosed with childhood B-ALL ( n = 5), adult 2), and 25) who were treated tisa-cel under non-clinical trial conditions. The goal was to determine how intensive pretreatment affects produced cells, their in vivo expansion, outcome therapy. Multiparametric flow cytometry used analyze material manufacturing cells...
Background The non-viral production of CAR-T cells through electroporation transposon DNA plasmids is an alternative approach to lentiviral/retroviral methods. This method particularly suitable for early-phase clinical trials involving novel types cells. primary disadvantage methods the lower efficiency compared viral-based methods, which becomes a limiting factor production, especially in chemotherapy-pretreated lymphopenic patients. Methods We describe good manufacturing practice...